MSK Clincal 2 Flashcards
(102 cards)
What evidence of autoimmunity is there in rheumatoid arthritis
High serum levels of autoantibodies such as rheumatoid factors and anti-citrullated peptide antibodies
They recognise either joint antigens or systemic antigens
- can be present for many years before the onset of clinical arthritis
The rheumatoid synovitis (pannus) is characterised by
inflammatory cell infiltration, synoviocyte proliferation and neoangiogenesis
Autoantibodies in seropositive rheumatoid arthritis
Rheumatoid factor
Anti citrullinated protein antibody
How does ACPA+ disease affect the prognosis of RA
Less favourable
Environmental factors that are associated with RA
Smoking and bronchial stress
Infectious agents - EBV, CMV, e.coli, mycoplasma, peridontal disease
What does repeated environmental insults in a susceptible individual lead to (in RA)
Formation of immune complexes triggers rheumatoid factor
Altered citrullination (change aminoacids) of proteins and breakdown of tolerance resulting in ACPA response
ACPA response in RA
Gingiva insult causes uptake Tcell activation in genetically susceptible individuals causing B cells and ACPA production (antibodies)
–> immune complexes
–> joint inflammation
(–>citrillinated human joint proteins
–> Immune complexes)
Systemic consequences of RA
Vasculitis, nodules, scleritis, amyloidosis = secondary to uncontrolled chronic inflammation
CV disease (altered lipid metabolism and increased endothelial activation)
Fatigue and reduced cognitive function
Liver (Elevated acute phase response; anaemia of chronic disease)
Lungs (interstitial lung disease, fibrosis)
Muscles - sarcopoenia
Bone - osteoporosis
Secondary sjorgen’s syndrome (multisystem autoimmune disease)
Male vs female prevalence of RA
1M: 3F
Drugs for symptomatic relief of RA
Analgesics +/- NSAIDs
Adverse effects of NSAIDs
GI irritation - indigestion, ulceration - consider PPI for gastroprotection
Bronchospasm in asthmatics
Renal impairment
Hypersensitivity reactions
Increased BP, fluid retention
Disease modifying anti-rheumatic drugs - DMARDS
Methotrexate Sulphasalazine Leflunomide Hydroxychloroquine Azathioprine Mycophenolate mofetil
Most effective DMARD
Methotrexate
Because faster onset of action (6 weeks to 3 months) compared to other
Can be given parenterally
Side effects of methotrexate
Nausea, stomatitis
Haematological toxicity
Hepatic toxicity
- LFTs, cirrhosis, hepatic fibrosis
Pulmonary toxicity
- TERATOGENIC
What can be given to reduce side effects of methotrexate
Folic acid
Biologics in RA
Specifically target pro-inflammatory mediators
Anti-TNF
- infliximab
Anti B cell
- rituximab
Safety concerns with biologic DMARDs
Serious infections Opportunistic infections (TB) Malignancies/lymphoma Demyelination Administration reactions Hepatic side effects Autoantibodies and drug induced lupus
Treatment of RA
Disease modifying anti-reumatic drugs
- methotrexate
- sulfasalazine
Corticosteroids
- prednisolone
Biologics
- anti TNF
- anti B
Osteoporosis risk factors
Old age
Genetic predisposition
Nutritional factors - low body weight and poor calcium and vit D
Immobility
Diseases influencing bone turn over; thyrotoxicosis, malabsorption, inflammatory arthritis
Medications: steroids, warfarin, TCA, diabetic medications, anticonvulsants
Antiresorptive agents for use in osteoporosis
HRT - not into 60s as increases stroke risk
SERMS
Biphosphonates (alendronate, risedronate)
RANKL inhibitors
Side effects of bisphosphonates
Oesophagitis
Iritis/uveitis
What is denosumab and what are the indications
Monoclonal antibody against RANKL
- for when bisphosphonates not well tolerated as treatment for osteoporosis
Reduces osteoclastic bone resorption
Subcut injection every 6 months
Side effects of denosumab
Allergy/rash
Symptomatic hypocalcaemia when vit D deplete
Side effects of strontium
Increased clotting risk
Increased cardiovascular risks